

B1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84303086.7

(51) Int. Cl.³: **C 12 Q 1/00**

C 12 Q 1/48, C 12 Q 1/54

(22) Date of filing: 08.05.84

(30) Priority: 05.05.83 GB 8312259
 05.05.83 GB 8312260
 05.05.83 GB 8312265
 06.09.83 GB 8323797
 06.09.83 GB 8323798
 29.02.84 GB 8405262
 29.02.84 GB 8405263

(43) Date of publication of application:
 14.11.84 Bulletin 84/46

(84) Designated Contracting States:
 BE CH DE FR GB IT LI NL

(71) Applicant: Genetics International, Inc.
 50 Milk Street Fifteenth Floor
 Boston, MA 02109(US)

(72) Inventor: Davis, Graham
 6 Heron Heights
 Goldington Green Bedfordshire(GB)

(72) Inventor: Hill, Hugh Allen Oliver
 9 Clover Close
 Oxford OX2 9JH(GB)

(72) Inventor: Cass, Anthony Edward George
 61 Geary Road Dollis Hill
 London NW10 1HJ(GB)

(74) Representative: Clifford, Frederick Alan et al.
 MARKS & CLERK 57/60 Lincoln's Inn Fields
 London WC2A 3LS(GB)

(54) Assay systems utilising more than one enzyme.





(57) This specification discloses assay systems which detect the presence of, or measure or monitor the extent of, an enzyme-catalysed reaction on a substrate. The systems of the present invention can be used to detect or measure the enzyme or the substrate, depending upon circumstances.

The specification further discloses a method of assay of the type in which an electrode (1) poised at a suitable potential is contacted with a system comprising a first enzyme, (GO) a substrate (G) which undergoes a reaction catalysed by the said enzyme, and a mediator compound (F) which transfers charge to the electrode (1) from the first enzyme (GO) when it is catalytically active, whereby the current flowing in the electrode is a measure of the reaction taking place; in which at least one further enzyme (HK) and associated compound (ATP) is incorporated into the system, the further enzyme (HK) being productive of, or also being reactive with, the substrate (G) so as to affect its presence or level, but not being electrochemically linked by the mediator (F) to the electrode (1), whereby the consequent difference in electrode current flowing with, and in the absence of, the second enzyme (HK) and its associated compound is a measure of the extent of reaction of the further enzyme with its associated compound and thus permits the amount of one to be established if the amount of the other is known.

There are two main subdivisions of the present disclosure (i) in which the electrode is provided at its surface with the first enzyme and the mediator compound to constitute a sensor electrode and (ii) in which the further enzyme exerts a catalytic change on a specific further substrate to yield substrate for the first enzyme.

EP 0 125 136 A2

/...



M&C FOLIO: 230P46071Y

WANGDOC: 0145s

Title:- ASSAY SYSTEMS UTILISING MORE THAN ONE ENZYME

This invention relates to essay systems which detect the presence of, or measure or monitor the extent of, an enzyme-catalysed reaction on a substrate. The systems of the present invention can be used to detect or measure
5 the enzyme or the substrate, depending upon circumstances.

Our European Patent Application 82305598 describes and claims a sensor electrode which comprises at least at an extreme surface thereof a combination of an enzyme and a
10 mediator compound which transfers charge to the electrode when the enzyme is catalytically active. Such an electrode, when contacting the specific substrate for the enzyme and poised at a suitable potential gives a signal responsive to the presence of, or indicative of
15 the extent of, the enzyme/substrate reaction, even in a complex mixture of substrates since the enzyme is specific to the desired substrate component.

The practical operation of such a system depends on the incorporation of the mediator compound. A number of
20 types of such compounds are disclosed in that application, such as polyviolegens, fluoranil,

chloranil, etc; but the mediators with best characteristics are metallocenes.

Ferrocenes (bis-cyclopentadienyl iron and its derivatives) fall within the last above named group and have advantages over other mediators used with enzyme/substrate reactions for charge-transfer purposes.

The unique structure and properties of ferrocene ($\text{Fc}p_2$) and its derivatives have resulted in a considerable amount of theoretical and experimental studies. First synthesised in 1951, ferrocene itself was the earliest example of the now well-known metallocene compounds.

Whilst ferrocenes had been found to be of limited value in spectrophotometric assays as a result of their poor solubility in aqueous solution and low extinction coefficients, they have been found to be more suited to a bio-electrochemical system. Ferrocenes have:

(a) a wide range of redox potentials accessible through substitution of the cyclopentadienyl rings, which can be functionalised;

(b) electrochemically reversible one-electron redox properties;

(c) the pH-independent redox potential and the slow autoxidation of the reduced form.

These compounds lend themselves to the formation of derivatives, e.g. by substitution of one or both
 5 cyclopentadienyl rings and/or by polymerisation. We have studied a number of derivatives of ferrocene such as those listed in the table below;

	Ferrocene derivative	E^0	Solubility	E
	1,1'-dimethyl-	100	I,D	-
10	acetic acid	124	S	370
	hydroxyethyl-	161	S	-
	ferrocene	165	I,D	335
	1,1'-bis(hydroxymethyl)-	224	S	385
	monocarboxylic acid	275	S	420
15	1,1'-dicarboxylic acid	³ 2 85	S	-
	chloro-	345	I,D	-
	methyl trimethylamino-	400	S	-

S indicates water solubility; I,D mean respectively insoluble and detergent solubilised in 3% Tween-20.

20 E^0 is in mV vs a standard calomel electrode, E is measured in $\text{cm}^{-1}\text{M}^{-1}$.

The E^0 values of various ferrocenes in phosphate buffer at pH 7.0 given in the above table, span a range

of potentials, $E^{\circ} = 100$ to 400mV vs SCE. The trend in E° values is in agreement with that expected on the basis of substituent effects. In general electron-donating groups stabilize the positive charge and hence promote oxidation more than electron withdrawing groups.

Of the above we find 1,1-dimethylferrocene and ferrocene monocarboxylic acid to be generally preferable because of their particularly wide range of accessible enzymes.

10 Although the invention described in our earlier application was particularly adapted to the use of glucose as the substrate and glucose oxidase or dehydrogenase as the enzyme (thereby to provide, for example, a glucose sensor of use in the diagnosis and
15 treatment of diabetic conditions) it was of general applicability, and other enzyme/substrate pairs such as those listed in the table following;

	<u>Enzyme</u>	<u>Substrate</u>
	<u>Flavo-proteins</u>	
	Pyruvate Oxidase	Pyruvate
	L-Amino Acid Oxidase	L-Amino Acids
5	Aldehyde Oxidase	Aldehydes
	Xanthine Oxidase	Xanthines
	Glucose Oxidase	Glucose
	Glycollate Oxidase	Glycollate
	Sarcosine Oxidase	Sarcosine
10	Lactate Oxidase	Lactate
	Glutathione reductase	NAD(P)H
	Lipoamide Dehydrogenase	NADPH
	<u>PQQ Enzymes</u>	
	Glucose Dehydrogenase	Glucose
15	Methanol Dehydrogenase	Methanol and other Alkanols
	Methylamine Dehydrogenase	Methylamine
	<u>Haem-Containing Enzymes</u>	
	Lactate Dehydrogenase	Lactate
	(Yeast Cytochrome B2)	
20	Horse-radish Peroxidase	Hydrogen Peroxide
	Yeast Cytochrome C	
	Peroxidase	Hydrogen Peroxide
	<u>Metalloflavoproteins</u>	
	Carbon monoxide	Carbon Monoxide
25	Oxidoreductase	
	<u>Cuproproteins</u>	
	Galactose Oxidase	Galactose

have been shown to give useful readout signals when
incorporated into such systems.

Nonetheless, not all enzyme/substrates are convenient for use in this known system, e.g. because of the unavailability or instability of the enzyme or substrate, or the difficulty in transferring to a usable form the electronic changes in the enzyme during catalytic reaction.

The present invention therefore sets out to provide a modified and elaborated system of assay utilising at least one further enzyme component.

10 In one aspect the invention consists in a method of assay of the type in which an electrode poised at a suitable potential is contacted with a system comprising a first enzyme, a substrate which undergoes a reaction catalysed by the said enzyme, and a mediator compound
15 which transfers charge to the electrode from the first enzyme when it is catalytically active, whereby the current flowing in the electrode is a measure of the reaction taking place; in which at least one further enzyme and associated compound is incorporated into the
20 system, the further enzyme being productive of, or also being reactive with, the substrate so as to affect its presence or level, but not being electrochemically linked by the mediator to the electrode, whereby the consequent difference in electrode current flowing with,

and in the absence of, the second enzyme and its associated compound is a measure of the extent of reaction of the further enzyme with its associated compound and thus permits the amount of one to be
5 established if the amount of the other is known.

Our copending application of even date entitled "Analytical Equipment and Sensor Electrodes therefor" describe the nature and manufacture of sensor electrodes. Such electrodes are preferred in the
10 practice of the present invention in which preferably the electrode is provided at its surface with the first enzyme and the mediator compound to constitute a sensor electrode.

However, our further copending application of even date
15 entitled "Assay techniques utilising Specific Binding Systems" and relating to specific binding agents (antibodies, or nucleic acid sequences) and their effect on the enzymes or mediators as an assay tool, describes systems in which the electrode can be a clean carbon
20 rod, or having only the mediator, or only the enzyme, or occasionally include a substrate. Such systems can be incorporated into the present invention if desired, which is not limited to sensor electrodes per se but is concerned with the overall method of assay irrespective
25 of the details of the embodying system.

There are two main subdivisions of the present invention (i) in which the electrode is provided at its surface with the first enzyme and the mediator compound to constitute a sensor electrode and

- 5 (ii) in which the further enzyme exerts a catalytic change on a specific further substrate to yield substrate for the first enzyme.

In the first subdivision it is preferred to operate so that (a) a sensor electrode provided at its surface with
10 the first enzyme and with the mediator compound is contacted with a substrate to give a steady current reading (b) the second enzyme and associated compound one of which is in unknown quantity are added to set up a competitive reaction and hence decrease the electrode
15 current and (c) the rate or extent of decrease, or the extent of substrate addition necessary to compensate for the decrease in electrode current, is noted as a measure of the amount of unknown component.

In this method the further enzyme is preferably a
20 kinase, e.g. a hexokinase, and the associated compound a phosphate-rich compound e.g. ATP.

One specifically valuable form of the invention consists in a method of assay for the unknown one of the pair of

compounds hexokinase and ATP, used in a combination where the amount of one is known, which comprises :

(a) contacting with a solution of glucose an electrode having at its surface a glucose oxidoreductase and a
5 mediator compound to transfer charge from the said enzyme to the electrode when the enzyme is catalytically active, thereby to set up a steady electrode current based on the glucose level,

(b) adding to the solution the hexokinase and ATP, so
10 as to set up with the glucose a competitive phosphorylation to which the electrode is insensitive, whereby the steady current is correspondingly reduced and,

(c) deriving a value for the unknown level from the rate
15 of, extent of, or glucose compensation for, the reduction in current.

Another specifically valuable form of the invention consists in a method of assay for creatine kinase, which comprises:

20 (a) contacting with a mixed solution of hexokinase, adenosine disphosphate, creatine phosphate and glucose an electrode having at its surface a glucose

oxidoreductase enzyme and a mediator compound to transfer charge from the enzyme to the electrode when the enzyme is catalytically active, thereby to set up a steady electrode current based on the glucose level,

- 5 (b) adding to the solution a creatine kinase to be assayed, under conditions in which adenosine diphosphate (ADP) is converted to adenosine triphosphate (ATP) by reaction of the creatine phosphate and so that consequentially the glucose is reacted, in competition
10 with the oxidoreductase enzyme reaction, to glucose-6-phosphate by the hexokinase and ATP phosphorylation to which the electrode is insensitive, whereby the steady current is correspondingly reduced, and
- 15 (c) deriving a value for the unknown creatine kinase level from the rate of, extent of, or glucose compensation for, the reduction in current.

Yet another specifically valuable form of the invention is a method of assay for creatine which comprises:

- 20 (a) contacting with a mixed solution of hexokinase, adenosine triphosphate (ATP), creatine kinase and glucose an electrode having at its surface a glucose oxidoreductase enzyme and a mediator compound to

transfer charge from the enzyme to the electrode when the enzyme is catalytically active, thereby to set up a steady electrode current depending on the available glucose level remaining after the competitive

5 ATP/hexokinase phosphorylation reaction to glucose-6-phosphate to which the electrode is insensitive, whereby the steady current is correspondingly reduced;

(b) adding to the solution creatine to be assayed under

10 conditions in which ATP is converted to ADP, with the formation of creatine phosphate, by the creatine kinase, and thereby decreases the amount of ATP available for the competitive glucose phosphorylation reaction,

(c) deriving a value for the unknown creatine level

15 from the rate of, or extent of alteration in electrode current.

The second subdivision of the invention lends itself to the fabrication of rather more elaborate electrodes. Thus, the electrode itself may be provided with the

20 first enzyme, the mediator compound therefor, and the further enzyme to constitute a sensor electrode for the said further substrate.

For instance, the electrode may be coated with sarcosine

oxidase or dehydrogenase, creatinase, and a mediator to transfer charge from the sarcosine to the electrode, and is contacted with a solution containing creatine for assay thereof by conversion to sarcosine.

- 5 For further example, the electrode may be coated with sarcosine oxidase or dehydrogenase, creatinase, creatininase, and a mediator to transfer charge from the sarcosine to the electrode, and is contacted with creatinine for assay thereof by serial conversion to
10 creatine and sarcosine.

As described in our earlier applications the preferred enzyme is a glucose oxidase or pyrroloquinoline quinone dehydrogenase (for the kinase/ATP methods) and generally speaking the ferrocenes are preferred mediators.

- 15 One further possible addition to which this invention lends itself is the idea of chemical combination of enzyme and mediator. It is possible as described in detail in our copending Application referred to above and entitled "Assay techniques utilising Specific
20 Binding Systems", with the protein structure of a glucose oxidase, to combine chemically up to 8 to 12 ferrocene units with the enzyme prejudicing its enzymatic activity. Such modified enzyme/mediator combinations can be used in the present
25 invention.

The invention will be further described with reference to the accompanying drawings, in which :-

Figure 1 shows a scheme of competitive glucose oxidase/glucose and hexokinase/glucose reactions, used
5 to detect or measure ATP or hexokinase;

Figure 2 shows a similar reaction further modified to detect or measure creatine kinase;

Figure 3 shows a similar reaction further modified to detect or measure creatine;

10 Figure 4 shows a scheme of reaction to detect or assay creatinine;

Figure 5 shows graphically the effect of adding creatine kinase to a steady state solution as described with reference to Figure 2; and

15 Figures 6 to 13 show graphically voltammograms and derived graphical results from specific experiments carried out.

A glucose sensor electrode was made up starting from a carbon rod. On this was deposited a solution of
20 1,1'-dimethylferrocene in toluene. The toluene was

permitted to evaporate, to leave a layer of the
1,1'-dimethylferrocene, over which was applied by
carbodiimide bonding the enzyme glucose oxidase.
Adjacent to but not contiguous with this composite
5 electrode was provided a standard calomel electrode.

Our copending European patent application 8230559
referred to above, and our prior copending application
entitled "Analytical Equipment and Sensor Electrodes
therefor" describe in detail the fabrication and
10 constructional features of numerous types of electrode
of the above general type. Their disclosures are
incorporated herein by way of reference. Such a
ferrocene/glucose oxidase electrode per se is not the
subject of the present invention.

15 If the electrode as made up above is poised at + 150mV
against the standard calomel electrode (SCE) it will
respond, linearly over a useful range, to the available
glucose level in a liquid substrate with which it is
contacted.

20 In the earlier invention, the glucose level of a
substrate was determined. In the present invention as
exemplified by Figure 1, a known initial level of
glucose (G) is usually used (or at least an
adequate level), and a competitive reaction is set up for

this glucose which can either react with the glucose oxidase GO to provide electron transfer i.e. charge transfer via the ferrocene to the electrode (as before) or react with added hexokinase enzyme (HK) and adenosine triphosphate (ATP), a reaction which is not linked with the electrode. In the first case glucose oxidation products are produced, such as glyceraldehyde or gluconolactone depending on the enzyme; in the second, glucose-6-phosphate, with the ATP being converted to ADP (adenosine diphosphate). The higher the concentrations of ATP and HK, the greater the extent to which this competing reaction decreases the expected reading of electrode current. If the HK concentration is known, the ATP concentration can be deduced, and vice versa. Of course, the electrode could also be used for a qualitative indication, i.e. mere detection of the HK/ATP presence.

Figure 2 illustrates another possible configuration of the assay system using an electrode made up as before. In this embodiment the assay measures the concentration of the enzyme creatine kinase (CK) (E.C. 2.7.3.2) which converts the phosphoguanidine, creatine phosphate, CP to creatine CN (The system could equally well assay enzymes which have as substrates phosphoguanidines other than creatine phosphate, such as arginine phosphate; or by a suitable selection of enzyme the system could assay

other phosphorylated substrates, such as phosphoenol pyruvate).

In operation, a liquid system is buffered in Tris/HCl contains 20mM Glucose (G) at pH 7, creatine phosphate (CP) (20mM), adenosine diphosphate (ADP) (5mM) and hexokinase (HK) 20m.ml). It is contacted with the 1,1'-dimethylferrocene/glucose oxidase electrode, and gives a steady reading as glucose is oxidised to its oxidation product GL. If creatine kinase is added then phosphate is removed from the creatine phosphate to leave creatine molecule. This phosphate is transferred to the adenosine diphosphate (ADP) by the creatine kinase to yield adenosine triphosphate (ATP). This in turn reacts with glucose in a reaction catalysed by the enzyme hexokinase thereby phosphorylating the glucose and forming glucose-6-phosphate, (GP) this reaction being competitive with the glucose oxidation reaction induced at the electrode. As a result, the activity of the glucose in solution, and hence the current at the electrode, decreases. The phosphorylated glucose is not active at the electrode.

The concentration of the creatine kinase may be estimated by calculating the rate of decrease of current at the electrode; by titrating with glucose until the original current is restored; or by allowing the system

to reach a steady state and comparing a final current reading with an initial current reading. Figure 5 illustrates how the initial steady catalytic current obtained with a system such as that described above with reference to Figure 2 falls when a solution containing creatine kinase is added to the system.

The creatine kinase assay give a linear response in the range $10-10^4$ Units/litre and can therefore be used in the diagnosis of a wide range of conditions, for example myocardial injuries (such as acute myocardial infarction or facultative myocardial injury) delirium tremens and muscular dystrophy, all of which cause elevated creatine kinase levels in the blood.

Figure 3 illustrates a further possible embodiment which may be employed to detect the substrate creatine. In this embodiment which is buffered at pH 9, the direction of the reaction catalysed by creatine kinase is reversed.

In operation, a steady-state system is prepared as before, but with glucose (G), hexokinase (HK), creatine kinase (CK) and adenosine triphosphate (ATP). When a glucose 1,1'-dimethylferrocene electrode as described above is introduced into the solution, the steady-state electrode current will be less than that available with the glucose level above, because the adenosine

triphosphate drives phosphorylation of the glucose in solution to GP(glucose-6-phosphate) and therefore reduces the activity of glucose at the electrode. In other words, a competitive reaction of known extent is set up, and stabilises.

If into this known competitive reaction a sample containing creatine is introduced the creatine will also be phosphorylated by the creatine kinase, with a corresponding reduction in the level of adenosine triphosphate; in other words a second, unknown, level of competitive reaction arises. The amount of creatine kinase available to transfer phosphate to glucose to yield glucose-6-phosphate is therefore decreased, since some is used to convert creatine to creatine phosphate.

It is possible to assay the level of creatine added if the other variables are known, or if the creatine added is known it is possible to assay the level of adenosine triphosphate, in each case simply by observing the change in activity at the electrode. An assay system according to the present invention may be used with plasma and generally speaking can be embodied for use with any biological fluid such as serum, urine, interstitial fluid, whole blood, saliva, etc. We have discovered that activity of (for example) creatine kinase in buffer, correlates well

(cc \approx 0.99) with the activity of the enzyme in plasma.

Various modifications may be made within the scope of this embodiment. For example, a further enzyme may be incorporated to convert creatinine to creatine thus
5 allowing assay systems to be constructed for creatinine, although Fig. 4 below shows an alternative assay system for creatinine.

Figure 4 shows a different type of assay technique which does not depend on competitive reaction for substrate,
10 and which utilises different enzymes suitable for the assay of glycine derivatives.

In the operation of the method shown in Fig. 4 an electrode is made up as described above, and in our corresponding applications incorporated herein by way of
15 reference; but instead of immobilising glucose oxidase on the electrode surface there is immobilised on the surface a mixture of sarcosine oxidase, creatininase (creatinine aminohydrolase) and creatinase (creatin amidinohydrolase).

20 Sarcosine (N-methylglycine) is an intermediate in the metabolism of one-carbon compounds, and a constituent of the actinomycins, a potent group of antimetabolites.

Sarcosine oxidase is found in liver and kidney mitochondria, and may be obtained also from microbial sources for example, from cells of species of coryneform bacteria. Sarcosine dehydrogenase may be obtained from
5 cells of a Pseudomonad. When the electrode is contacted with a substrate containing creatinine

(a) creatine is formed from creatinine by the action of creatininase

(b) sarcosine is formed from creatine by the enzyme
10 creatinase and

(c) glycine is formed from sarcosine by the enzyme sarcosine oxidase, which passes electrons to the electrode via the ferrocene to give a readout signal quantitatively related to the creatinine concentration.

15 The electrode current measured in a suitably calibrated device is a measure of the concentration of the creatinine.

The invention will be further described with reference to the following specific Examples.

Example 1

To the working compartment of a two-compartment electrochemical cell incorporating a 4mm diameter gold working electrode, a 0.5cm² platinum gauze counter electrode and a saturated calomel reference electrode (SCE), separated from the working compartment by a Luggin capillary, was added 1ml of Tris/HCL buffer (50mM, pH 7.5) containing ferrocene monocarboxylic acid (200 μ M).

Figure 6 shows a D.C. cyclic voltammogram obtained at a scan rate of 5mVs⁻¹ over the range 0 to +500 mV vs. SCE. The forward and reverse electrochemical waves are consistent with the reversible couple $E_{1/2}$ (Ferrocene monocarboxylic acid/ferricinium monocarboxylic acid) = +275 mV vs. SCE, where $E_{1/2}$ is the half wave potential of the system.

Subsequent serial addition of sarcosine dehydrogenase 50 IU ml⁻¹ and creatinine amidohydrolase 50 IU ml⁻¹ had no effect upon the reversible electrochemistry of ferrocene-monocarboxylic acid, curve (a).

However, upon further addition of creatinase (5mM) voltammogram (b) was obtained. The enhanced anodic current is indicative of a catalytically coupled

reaction in which ferrocene monocarboxylic acid is regenerated from the ferricinium ion by reaction via reduced sarcosine dehydrogenase.

This behaviour is only observed when all of the reaction components are present. Addition of creatinine, creatine and sarcosine, 5mM respectively, to the system in the absence of any of the enzymes has no effect upon the electrochemistry of ferrocene monocarboxylic acid. Also, in another example, addition of the buffer, creatinine, ferrocene monocarboxylic acid, creatine amidinohydrolase and sarcosine dehydrogenase gave no catalytic current but only the forward and return runs for the ferrocene monocarboxylic acid until creatinase was added.

All materials that were used were supplied by Sigma Chemical Company.

Example 2 - Assay for Creatine Kinase.

(a) General

The sudden and complete occlusion of the coronary artery by a thrombosis cuts the blood supply to a zone of myocardial tissue depriving it of oxygen and glucose. Damage to the affected muscle leads to a release of cardiac enzymes into the blood circulation. The enzyme

creatine kinase, [EC 2.7.3.2] (CK), constitutes ca. 20% of the soluble sarcoplasmic protein of heart muscle. Consequently, the occurrence of elevated levels of CK in the blood often results in the diagnosis of acute myocardial infarction (AMI).

Several methods for measuring CK activity in plasma have been devised and are in daily use in clinical biochemistry laboratories, to perform over 30 million determinations per year.

10 Creatine kinase catalyses the reversible transfer of a phosphate residue from adenosine-5'-triphosphate (ATP) to creatine.

The reaction product, creatine phosphate, represents an essential energy store for contraction, relaxation and transport of substances within muscle cells.

Creatine kinase is a dimeric enzyme, molecular weight 82 000, constituted of two subunits weighing 41 000 (3). In human tissue two different types of subunits exist, designated M (muscle) and B (brain). The dimeric enzyme can have the following forms: CK-MM skeletal muscle type, CK-BB brain type and CK-MB myocardial type. These isoenzymes can be separated by electrophoretic techniques or by an immuno-inhibition

method based on the use of goat anti-human CK-MB antibody. Methods of separating the different isoenzymes are of clinical importance, since elevated isoenzyme levels in plasma have been detected and found to be associated with causes other than AMI e.g. surgery, muscular dystrophy and muscular injury, and strenuous exercise. These are listed in table I. Whilst this may appear to negate the significance of a total plasma CK assay to AMI, in practice the assay remains of great value since other clinical factors are also taken into account before a diagnosis is made.

TABLE I

Condition	Total CK activity	CK-MB activity
	U/L	U/L
Acute myocardial infarction	30-1970	6-232
15 Cardiogenic shock	90-860	5-114
Polytrauma with myocardial injury	110-2640	8-196
Cardiogenic defibrillation	180-580	9-41
Duchenne muscular dystrophy	400-4550	31-280
Delerium tremens	88-13510	4-830
20 Orthopaedic operations	15-630	0-18
Head injury	153-380	0-18

25

Condition	Total CK activity	CK-MB activity
	U/L	U/L
Neurosurgical operations	63-610	0-88
5 Weight lifters	110-740	0-10
Polytrauma without myocardial injury	76-6220	0-230

The rapid response time of the ferrocene-based glucose enzyme electrodes indicates that in addition to

10 monitoring bulk glucose concentrations, the device could be used to monitor the rates of change in bulk glucose concentrations. Thus CK activity could be determined using the coupled reactions sequence shown e.g. in Fig. 2 with the glucose enzyme electrode monitoring the rate

15 of consumption of glucose. Under optimised conditions the rate of decrease in the electrode current should be proportional to the rate of consumption of glucose, which in turn would be proportional to the rate of consumption of creatine phosphate, from which the

20 activity of CK can be estimated.

(b) Reagents

Creatine phosphate, adenosine-5'-diphosphate, adenosine-5'-triphosphate, creatine kinase from rabbit muscle with an activity of 800 IU mg⁻¹ at 37°C and

25 hexokinase from yeast with an activity of 1600 IU ml⁻¹

at 37°C were supplied by Boehringer. D-glucose and magnesium chloride were of AnalaR grade and supplied by BDH. In all experiments 25mM tris(hydroxymethyl)aminomethane, adjusted to pH 7.0 with
5 HCl, was used.

(c) Electrochemical experiments

D.C. cyclic voltammetry experiments were carried out with the cell described in Example 1 using a 4 mm diameter pyrolytic graphite working electrode.

10 Experiments in which the glucose enzyme electrode was used were performed with the first prototype design a 1ml three-compartment electrochemical cell, equipped with a stirrer bar. The rate of change in the steady-state glucose-dependent current was measured with
15 the glucose enzyme electrode poised at 160mV vs SCE, using an Oxford electrodes potentiostat and a Bryan BS-271 chart recorder.

All assays were performed under thermostatic control at 37°C.

20 (d) Plasma samples

Heparinised plasma samples were supplied frozen by the

Clinical Biochemistry Laboratory of the John Radcliffe
Hospital, Oxford.

(e) Uncoupling the glucose oxidase reaction

Figure 7 shows at (a) a D.C. cyclic voltammogram of
5 ferrocene monocarboxylic acid in 25mM Tris-HCl buffer,
pH 7.0, containing 20mM magnesium chloride and 10mM
glucose. Addition of glucose oxidase, gave curve (b)
showing a typical catalytic current at oxidising
potentials, resulting from the enzymatically coupled
10 oxidation of glucose. When hexokinase 20 IU ml^{-1} , is
added, no change in the voltammogram is observed.
However, upon addition of ATP to a final concentration
of 10mM, the catalytic behaviour is no longer observed
and the voltammogram associated with reversible
15 electrochemistry of the ferrocene is again obtained, at
at (a). These observations are consistent with
phosphorylation of glucose to form glucose-6-phosphate,
thus removing from solution the substrate for the
electrochemically coupled oxidation reaction.

20 Since none of the components of the system interfered
with the electrochemistry of ferrocene monocarboxylic
acid, or showed any direct electrochemistry over the
range of potential scanned, 0-450mV vs SCE, it was
possible to investigate the response of the glucose

enzyme electrode, firstly as an ATP monitor, and then for monitoring kinase activity.

(f) Glucose enzyme electrode as an ATP sensor

Figure 8 shows a trace of the current-time response of a glucose enzyme electrode in 10mM glucose and hexokinase 20 IU ml⁻¹. A series of five aliquots of ATP (each to a final concentration of 2.0mM) were added and the decrease in the steady-state current was measured after each addition. Figure 9 plots the steady-state current as a function of ATP added. Figure 10 correlates the amount of glucose consumed with the amount of ATP added, from which a correlation coefficient of 0.99 was calculated. This experiment shows that the glucose enzyme electrode can be used to monitor stoichiometric consumption of glucose by ATP, in the presence of hexokinase. The electrode is re-usable: figure 8 shows that the electrode responds to further addition of glucose at the end of the experiment.

(g) Glucose enzyme electrode based creatine kinase assay

Figure 11 shows that the current-time response of the glucose enzyme electrode in 20mM glucose is stable, after the further addition of hexokinase 20 IU ml⁻¹, ADP (5.0mM) and creatine phosphate (20mM). These

reagent concentrations were found to be in sufficient excess to ensure that the rate of glucose consumption in the assay was limited by the activity of creatine kinase. When creatine kinase, with a reported activity of 500 IU l⁻¹ is added to the system, the current decreases with time. From the initial rate of decrease, the rate of glucose consumption was calculated. The rate of glucose consumption should be equivalent to the activity of creatine kinase in μ moles creatine phosphate consumed min⁻¹ mg⁻¹. From the results a correlation coefficient of 0.99 was calculated. (Fig. 12).

(h) Detection limits of Creatine kinase assay

In post-AMI patients, plasma CK activities in the range 30-2000 IU l⁻¹, are common. The assay procedure, when investigated in buffered solutions, is accordingly expected to be suitable for monitoring clinical levels of CK (see Fig. 12). The upper limit of the electrode response is ca. 10 IU ml⁻¹ (10 000 IU l⁻¹).

(i) Assay of creatine kinase in plasma samples

It was not possible to obtain authentic plasma samples from post-AMI patients, so samples were simulated by adding clinically relevant concentrations of CK to human plasma. Aliquots of ADP, MgCl₂ and HK were also added

to the plasma to give the same reagent concentrations as used above. The initial glucose concentration present in the plasma was determined with the glucose enzyme electrode, and was increased to 20mM by adding glucose.

- 5 The reaction was initiated by the adding of creatine phosphate. Table II shows data obtained for the activity of creatine kinase as supplied, in buffer at pH 7.0 and in plasma at pH 7.7. The data for plasma are normalised to pH 7.0, as the activity of CK (for the
- 10 reverse reaction) is lower at pH 7.7 than at Ph 7.0. A correlation plot for the normalised data is presented in figure 13 from which a correlation coefficient of 0.97 was obtained, $n=9$, $y=-1.05 \pm 0.08$.

- The performance of the glucose enzyme electrode-based
- 15 assay for creatine kinase in plasma suggests that the method could undergo a more detailed comprison with present methods using authentic post-AMI samples. In addition, the enzyme electrode could be further refined by the co-immobilisation of glucose oxidase and
- 20 hexokinase, thus eliminating the necessity to add the latter to the assay sample.

TABLE II

	CK Added	Buffer pH 7.0	Plasma pH 7.7	Plasma correc- ted to
	IU/L	IU/L	IU/L	pH 7.0 IU/L
5	150	152	64.7	154
	150	152	66.8	159
	150	148	59.6	142
	90	83	37.0	88
	70	76	31.5	75
	30	31	2.5	5.9
	15	15	1.9	4.5
10	7.5	7.3	2.3	5.3
	7.5	7.3	3.6	8.6

CLAIMS

1. A method of assay of the type in which an electrode
poised at a suitable potential is contacted with a
system comprising a first enzyme, a substrate which
undergoes a reaction catalysed by the said enzyme, and a
5 mediator compound which transfers charge to the
electrode from the first enzyme when it is catalytically
active, whereby the current flowing in the electrode is
a measure of the reaction taking place: in which at least
one further enzyme and associated compound is
10 incorporated into the system, the further enzyme being
productive of, or also being reactive with, the
substrate so as to affect its presence or level, but
not being electrochemically linked by the mediator to
the electrode, whereby the consequent difference in
15 electrode current flowing with, and in the absence of,
the second enzyme and its associated compound is a
measure of the extent of reaction of the further enzyme
with its associated compound and thus permits the amount
of one to be established if the amount of the other is
20 known.
2. A method as claimed in claim 1 in which the
electrode is provided at its surface with the first
enzyme and the mediator compound to constitute a sensor
electrode.

3. A method as claimed in claim 1 in which the further enzyme exerts a competitive reaction on the substrate and thus leads to a decrease in current flowing in the electrode.

5 4. A method as claimed in claim 3 in which (a) a sensor electrode provided at its surface with the first enzyme and with the mediator compound is contacted with a substrate to give a steady current reading (b) the second enzyme and associated compound one of which is in
10 unknown quantity are added to set up a competitive reaction and hence decrease the electrode current and (c) the rate or extent of decrease, or the extent of substrate addition necessary to compensate for the decrease in electrode current, is noted as a measure of
15 the amount of unknown component.

5. A method as claimed in claim 3 or 4 in which the further enzyme is a kinase and the associated compound is a high energy phosphate.

6. A method as claimed in claim 3 or 4, in which the
20 further enzyme is a hexokinase and the associated compound is ATP.

7. A method of assay for the unknown one of the pair of compounds hexokinase and ATP, used in a combination

where the amount of one is known, which comprises:

(a) contacting with a solution of glucose an electrode having at its surface a glucose oxidoreductase and a mediator compound to transfer charge from the said enzyme to the electrode when the enzyme is catalytically active, thereby to set up a steady electrode current based on the glucose level,

(b) adding to the solution the hexokinase and ATP so as to set up with the glucose a competitive phosphorylation reaction to which the electrode is insensitive, whereby the steady current is correspondingly reduced.

(c) deriving a value for the unknown level from the rate of, extent of, or glucose compensation for, the reduction in current.

8. A method of assay for creatine kinase, which comprises:

(a) contacting with a mixed solution of hexokinase, adenosine diphosphate, creative phosphate and glucose an electrode having at its surface a glucose oxidoreductase enzyme and a mediator compound to transfer charge from the enzyme to the electrode when the enzyme is

active, thereby to set up a steady

electrode current based on the glucose level,

(b) adding to the solution creatine kinase to be assayed, under conditions in which adenosine diphosphate (ADP) is converted to adenosine triphosphate (ATP) by
5 reaction of the creatine phosphate and so that consequentially the glucose is reacted, in competition with the oxidoreductase enzyme reaction, to glucose-6-phosphate by the hexokinase and ATP
phosphorylation to which the electrode is insensitive,
10 whereby the steady current is correspondingly reduced, and

(c) deriving a value for the unknown creatine kinase level from the rate of, extent of, or glucose compensation for, the reduction in current.

15 9. A method of assay for creatine which comprises :
(a) contacting with a mixed solution of hexokinase, adenosine triphosphate (ATP), creatine kinase and glucose an electrode having at its surface a glucose
oxidoreductase enzyme and a mediator compound to
20 transfer charge from the enzyme to be electrode when the enzyme is catalytically active, thereby to set up a steady electrode current depending on the available glucose level remaining after the competitive
ATP/hexokinase phosphorylation reaction to

glucose-6-phosphate to which the electrode is insensitive, whereby the steady current is correspondingly reduced;

- (b) adding to the solution creatine to be assayed under
5 conditions in which ATP is converted to ADP, with the formation of creatine phosphate by the creatine kinase, and thereby decreases the amount of ATP available for the competitive glucose phosphorylation reaction.
- (c) deriving a value for the unknown creatine level from
10 the rate of or extent of alteration in electrode current.

10. A method as claimed in claim 1 in which the further enzyme exerts a catalytic change on a specific further substrate to yield substrate for the first enzyme.

11. A method as claimed in claim 10 in which the
15 electrode is provided with the first enzyme, the mediator compound therefor, and the further enzyme to constitute a sensor electrode for the said further substrate.

12. A method as claimed in claim 11 in which the
20 electrode is coated with sarcosine oxidase or dehydrogenase, creatinase, and a mediator to transfer a charge from the sarcosine to the electrode, and is

contacted with a solution containing creatine for assay thereof by conversion to sarcosine.

13. A method as claimed in claim 11 in which the electrode is coated with sarcosine oxidase or
5 dehydrogenase, creatinase, creatininase, and a mediator to transfer charge from the sarcosine to the electrode, and is contacted with creatinine for assay thereof by serial conversion to creatine and sarcosine.

14. A method as claimed in claim 1, 2, 3, 4, 7, 8 or 9
10 in which the first enzyme is a glucose oxidase.

15. A method as claimed in claim 1, 2, 3, 4, 7, 8 or 9 in which the first enzyme is a glucose dehydrogenase.

16. A method as claimed in claim 1, 2, 3, 4, 7, 8, 9, 10, 11, 12 or 13 in which the mediator is a ferrocene.

15 17. A method as claimed in claim 1, 2, 3, 4, 7, 8, 9, 10, 11, 12 or 13 in which the mediator is 1,1'-dimethylferrocene.




FIG. 1.




FIG. 2.




FIG. 3.




FIG. 4.

Addition Creating 125136
Kinase

2 μ A

6 minutes

FIG. 5.




FIG. 6.

3/8

0125136

13




FIG. 7.




FIG. 8




FIG. 9.




FIG. 10.

0125136

576

FIG. 12.

15





FIG. 11




FIG. 13.

